Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

revenues were due to payments received in previous years from NicOx' partnered programs with Merck & Co., Inc. in the antihypertensive field and Pfizer Inc in ophthalmology.

Operating expenses totaled EUR86.4 million in 2008, compared to EUR61.8 million in 2007. The majority of these expenses were associated with the phase 3 clinical program for naproxcinod in osteoarthritis (OA) patients, which was successfully completed in the second half of 2008. Naproxcinod is the first Cyclooxygenase-Inhibiting Nitric Oxide Donator (CINOD) and a New Drug Application (NDA) submission to the US Food and Drug Administration (FDA) is projected for mid-2009. NicOx' net loss was EUR73.9 million for the full year 2008, compared to EUR32.1 million in 2007.

On December 31, 2008, NicOx had cash, cash equivalents and financial instruments of EUR104.7 million, compared to EUR172.8 million on December 31, 2007.

Considerable progress made in naproxcinod pre-commercialization activities

In 2008, NicOx signed two major manufacturing agreements to prepare the commercial launch of naproxcinod. In September, an agreement was signed with Capsugel, for the commercial manufacture and supply of naproxcinod capsules and in December, an agreement was signed with DSM for the commercial manufacturing and supply of naproxcinod drug substance (Active Pharmaceutical Ingredient, API). The aim of these agreements is to ensure sufficient commercial supplies of naproxcinod to underpin its successful market launch.

NicOx is currently in discussions with a number of companies regarding a potential commercialization agreement for naproxcinod. NicOx aims to retain certain commercialization rights for naproxcinod, in order to fully exploit the drug's commercial and strategic value and aid the Company's planned transition to a self-sustainable pharmaceutical business.

Completed phase 3 program confirms naprox
'/>"/>

SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... 2014 The Europe Thermal Protective ... to provide crucial revenue forecasts. It estimates the ... at a CAGR of 7.5%, from 2013 to ... Europe Thermal Protective Clothing market report for a ... supported by various tables and figures. , ...
(Date:11/27/2014)... Nov. 27, 2014 Research and ... "Global Palmitic Acid Industry Report 2014" report to ... The Global Palmitic Acid Industry Report 2014 ... state of the global palmitic acid industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:11/27/2014)... 2014 Spartan Bioscience today announced that ... Drug Safety (MFDS) regulatory approval for its Spartan ... in less than 60 minutes from a non-invasive cheek ... aid for doctors to determine therapeutic strategies for drugs ... some of the world’s most commonly prescribed drugs such ...
(Date:11/27/2014)... November 27, 2014 First ...   Elsevier , a world-leading provider ... is pleased to announce the launch of a new ... The launch of Extreme Mechanics ... at the forefront of applied sciences such as micro ...
Breaking Biology Technology:The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 2The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 3Global Palmitic Acid Industry Report 2014 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 3Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3
... Inc., today,announced the appointment of Lynn Marcus-Wyner, Ph.D., ... for managing the company,s,intellectual property strategy, activities, and ... President, General Counsel and Secretary., Dr. Marcus-Wyner ... Intellectual Assets US, she managed the United States ...
... Sept. 23 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX: SDI) ... terms with Toray,Industries Inc. of Japan to obtain ... for Toraymyxin(TM), a therapeutic for the treatment of,sepsis ... terms of the,agreement, the Company will seek FDA ...
... BROOMFIELD, Colo., Sept. 23 ARCA biopharma, ... Drug Administration (FDA) has,accepted a New Drug ... bucindolol, an investigational and pharmacologically unique,beta-blocker and ... chronic,heart failure. If approved by the FDA, ...
Cached Biology Technology:Codexis Names Vice President, Intellectual Property 2Spectral to bring anti-sepsis therapy to the U.S. market 2Spectral to bring anti-sepsis therapy to the U.S. market 3FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma 2FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma 3
(Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
(Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
(Date:11/21/2014)... 2014 Strict laws against distracted driving and ... North American and European automotive sector towards gesture recognition ... systems that are intuitive and able to retrieve information ... New analysis from Frost & Sullivan,s ... Europe and North ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... [Brown University] Just as a company creates new, better ... its bottom line, an international team of researchers led by ... and performance before flooding the environment with new, improved versions ... plants with the same ancestor, called a clade, begin to ...
... growth and spread of breast cancer tumors may be ... strategies: blocking the enzyme needed to "energize" cancer cells ... with minimum exposure to healthy tissues, indicate researchers at ... in Chicago, Ill. "Once breast cancer metastases ...
... with information on the size of the carbon footprint ... make better, environmentally friendly choices. A Michigan State ... of the journal Nature Climate Change , said ... with nutritional information, could offer at least a short-term ...
Cached Biology News:Like products, plants wait for optimal configuration before market success 2Interventional radiologists provide hope in delaying growth, spread of breast cancer 2Interventional radiologists provide hope in delaying growth, spread of breast cancer 3Nature paper calls for carbon labeling 2
... genetically engineered Klenow polymerase in which the 3 ... only the 5 to 3 polymerase activity. The ... the enzyme of choice for isotopic or biotin ... method, and for DNA sequencing by the Sanger ...
... a DNA-dependent RNA polymerase which is stringently ... efficiently synthesizes in vitro transcripts from almost ... a T7 promoter. Transcripts can be ... vitro translation, substrates in RNA processing systems, ...
... overproducer ATP: D-hexose 6- phosphotransferase/D-glucose-6-phosphate: ... unit of HK will phosphorylate ... 1 min at 25C at ... G6P-DH will oxidize 1 mol ...
Goat polyclonal to Haptoglobin ( Abpromise for all tested applications). Antigen: Affinity purified human haptoglobin. Entrez GeneID: 3240 Swiss Protein ID: P00738...
Biology Products: